We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
From May 2019 to May 2024
By Bowdeya Tweh
Alexion Pharmaceuticals Inc. (ALXN) raised its profit and sales outlook this year after posting stronger-than-expected first-quarter results, bolstered by growth in Soliris and newer treatments like Ultomiris.
Profit in the latest period more than doubled to $587.9 million, or $2.61 a share.
Excluding one-time items, Alexion earned $2.39 a share. Analysts polled by FactSet expected $2.21 a share.
Revenue rose 23%, to $1.14 billion, as analysts expected $1.13 billion.
For the full year Alexion expects per-share earnings of $6.76 to $7.96, or $9.25 to $9.45 as adjusted, on revenue of $4.68 billion to $4.75 billion. The company had expected per-share earnings of $6.14 to $7.26, or $9.10 to $9.30 as adjusted, on $4.63 billion to $4.7 billion in revenue.
Write to Bowdeya Tweh at bowdeya.tweh@wsj.com
(END) Dow Jones Newswires
April 25, 2019 07:13 ET (11:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
